The FDA Just Approved a Herpes Virus to Kill Cancer. It Said No Twice. The Accessibility Math Against Its $515,000 Competitor Is the Real Story.
Tudriqev is a genetically engineered herpes simplex virus that infects tumors, kills cancer cells, and teaches the immune system to hunt the rest. The FDA rejected it twice in 13 months. An advisory panel voted 10-to-3. The approval creates a 50:1 treatment center advantage over the only other option for post-immunotherapy melanoma.
On Thursday, the FDA approved a genetically modified herpes virus to treat cancer, and that sentence is not a metaphor. An actual herpes virus, engineered in a lab, injected into tumors. The drug is called Tudriqev, made by Replimune, and it works by replicating inside cancer cells, rupturing them from the inside out, and then recruiting the patient's immune system to attack cancer cells the virus never touched, cells in distant organs the needle never reached, metastases the surgeon never saw. Replimune's virus is an engineered strain of herpes simplex virus type 1, the pathogen behind cold sores, rewired to become a weapon against one of the deadliest cancers on Earth.
Approval matters, but backstory matters more.
Twice, the FDA said no. Then it said yes. From first rejection to final approval, 13 months passed, two complete response letters were issued, a CEO publicly accused the regulatory system of killing patients, a company threatened to lay off its entire workforce and shutter its manufacturing operations, a reported appeal reached the White House, and an advisory panel voted 10 to 3 that the drug works. That is not how drugs usually get approved.
But the number that should dominate the conversation about Tudriqev has nothing to do with regulatory politics, advisory votes, or White House phone calls. It has to do with a treatment center count that nobody in the oncology industry has calculated, a count that exposes a structural gap so large it may determine which patients live and which die based not on biology but on zip code.
The Only Other Option Requires Surgery and Costs $515,000
Tudriqev enters a market with exactly one competitor: Amtagvi, made by Iovance Biotherapeutics, approved in February 2024 for the same indication. Both drugs target patients with advanced melanoma whose tumors have grown despite treatment with PD-1 checkpoint inhibitors like Keytruda or Opdivo, a population the American Cancer Society estimates at roughly 14,000 to 20,000 patients per year in the United States alone. About half of all advanced melanoma patients eventually progress on immunotherapy, and until 2024, they had essentially no approved options left.
How these two drugs reach a patient could not be more different.
| Dimension | Tudriqev (Replimune) | Amtagvi (Iovance) |
|---|---|---|
| Mechanism | Oncolytic virus + checkpoint inhibitor | Tumor-infiltrating lymphocyte (TIL) cell therapy |
| Step 1 | Inject virus into tumor (office visit) | Surgically harvest tumor tissue |
| Step 2 | Administer Opdivo IV (standard infusion) | Ship tissue to manufacturing facility |
| Manufacturing | None (virus is off-the-shelf) | 3-5 weeks of ex vivo T-cell expansion |
| Pre-treatment | None | Lymphodepletion chemotherapy |
| Administration | Intratumoral injection | Single IV infusion + ICU monitoring |
| Time to treatment | Days | 4-8 weeks |
| Price per course | Not yet announced | ~$515,000 |
| Certified U.S. centers | ~1,500+ (any oncology practice) | ~30 |
That last row changes everything: a fifty-to-one gap in accessibility.
The Throughput Ceiling Nobody Calculated
Amtagvi is a brilliant therapy that works precisely when it can reach a patient. Its 31.4% overall response rate in the pivotal C-144-01 trial, with 75% of responders maintaining their response beyond 12 months, is among the most durable results ever seen in refractory melanoma, the kind of data that makes oncologists rethink what they thought they knew about advanced disease, the kind that gives families months and years they had stopped expecting. It generated $220 million in sales in its first full year on the market. But it has a physics problem that no amount of commercial execution can solve.
Each Amtagvi treatment requires a surgical suite to harvest tumor tissue, a cGMP manufacturing facility to expand the patient's tumor-infiltrating lymphocytes over three to five weeks, and a certified treatment center equipped to administer lymphodepletion chemotherapy followed by the cell infusion with intensive monitoring. As of mid-2026, approximately 30 treatment centers in the United States are certified to deliver the full Amtagvi workflow.
Here is the math nobody has published. Each certified center, constrained by surgical scheduling, manufacturing turnaround, and post-infusion monitoring capacity, can realistically process 50 to 70 patients per year. At 30 centers:
| Parameter | Value |
|---|---|
| Certified U.S. treatment centers | ~30 |
| Patients per center per year | 50-70 |
| Maximum annual throughput | 1,500-2,100 |
| Estimated eligible U.S. patients per year | 14,000-20,000 |
| Patients structurally unreachable | 85-89% |
Even if every certified center ran at maximum capacity, Amtagvi could treat roughly 11 to 15 percent of eligible patients in the United States. For the other 85 to 89 percent, denial comes not because the drug does not work but because the infrastructure to deliver it does not exist where they live, because their oncologist is not at a certified center, or because the four-to-eight-week manufacturing window is longer than their disease will wait.
Tudriqev is an intratumoral injection that arrives as a vial. An oncologist injects it into the tumor, often guided by ultrasound or CT, in a procedure that takes minutes and requires no surgical suite, no manufacturing facility, and no ICU bed. Any oncologist at any cancer center with injection capability can administer it. In the United States, that is approximately 1,500 or more practices, roughly 50 times the number of Amtagvi-certified centers.
The Efficacy Trade-off Is Real
Tudriqev's response rate is lower, and that is the trade-off. In the IGNYTE trial data that the FDA used for its approval decision, 24.2% of patients responded, with a median duration of response of 14.1 months. An earlier data cut from the same trial, cited in Replimune's April 2026 filing, showed a 34% response rate with a median duration of 24.8 months in a per-protocol analysis, a difference that reflects different analysis populations and longer follow-up, which is standard for oncology trials but important to flag.
Amtagvi's 31.4% response rate with 75% durability beyond 12 months is objectively superior on paper. But oncology outcomes are not determined on paper. They are determined by which patients can actually receive the treatment. They are determined by distance, by scheduling, by whether the patient's local hospital has a cGMP manufacturing suite or an ICU bed available or a surgeon credentialed for tumor harvesting on a timeline the disease permits.
A drug with a 31% response rate that can reach 2,000 patients produces approximately 620 responses per year, while a drug with a 24% response rate that can reach 15,000 patients produces 3,600. The less effective drug saves nearly six times more lives.
| Drug | ORR | Reachable Patients/Year | Expected Responses/Year |
|---|---|---|---|
| Amtagvi (at throughput ceiling) | 31.4% | ~2,000 | ~628 |
| Tudriqev (at scale) | 24.2% | ~15,000 | ~3,630 |
| Tudriqev advantage | 7.5x reach | 5.8x responses |
This is not a critique of Amtagvi. TIL therapy is a remarkable achievement in cancer immunology, and the patients who can access it benefit enormously. This is structural: an off-the-shelf injectable that works somewhat less often but can be delivered everywhere will produce more survivors than a manufactured cell therapy that works more often but requires a surgical center most patients cannot reach.
The Herpes Virus, Rewired
Tudriqev's formal name is vusolimogene oderparepvec. It is built on a proprietary strain of herpes simplex virus type 1, the virus behind common cold sores, which has a natural affinity for human cells and a well-understood replication cycle. Replimune's engineers made three critical modifications.
First, they deleted the genes that allow the virus to evade the immune system, ensuring that infected cancer cells are flagged for destruction by the patient's own immune response. Second, they inserted a gene encoding a fusogenic protein called GALV-GP R-, borrowed from the gibbon ape leukemia virus, which causes infected cancer cells to fuse with their neighbors before dying, spreading the killing effect to cells the virus never directly entered. Third, they armed it with GM-CSF, a protein that recruits dendritic cells and macrophages to the tumor site, amplifying the immune response against tumor antigens released during viral killing.
What emerges is a dual-action weapon. Locally, the virus replicates inside tumor cells, ruptures them, fuses them with their neighbors, and spreads. Systemically, the immune response triggered by dying tumor cells teaches the patient's T cells to recognize and attack cancer cells throughout the body, including metastases the virus never reached, tumors in the liver or lung or brain that no needle ever touched. Combined with Opdivo, a checkpoint inhibitor that removes the brakes on T-cell activity, the systemic effect is amplified further still.
A 13-Month Regulatory War
Replimune first submitted its biologics license application in late 2024, seeking accelerated approval based on the IGNYTE trial. The FDA's first rejection came in July 2025, citing the single-arm study design and insufficient evidence of effectiveness. Replimune resubmitted in October 2025, adding new analyses. Again, the FDA rejected it on April 10, 2026.
CEO Sushil Patel's response was extraordinary by pharmaceutical industry standards. "Not because the medicine failed," he said in a public statement. "Because the system did." He announced that without approval, "we have no choice but to eliminate jobs, including substantially scaling back our U.S. based manufacturing operations. A treatment desperately needed by patients will not be available."
Replimune reportedly pushed the White House to intervene. Replimune resubmitted for a third time in June 2026. Regulators accepted the submission on an expedited timeline, convened an advisory panel that voted 10-to-3 that the data showed clinically meaningful benefit, and approved the drug on August 7. Three panelists who voted no cited the absence of a randomized control group.
Approval is accelerated, meaning Replimune must complete an ongoing confirmatory Phase 3 trial to demonstrate the drug's benefit in a controlled setting. If that confirmatory trial fails, the FDA can withdraw approval.
The Ghost of T-VEC
Tudriqev is not the first oncolytic virus approved for melanoma, a distinction that belongs to Amgen's Imlygic, also built on engineered HSV-1, which won FDA approval in 2015. Imlygic was a landmark and also a commercial failure.
T-VEC achieved a 16.3% overall response rate as monotherapy, lower than Tudriqev's 24.2% in combination with a checkpoint inhibitor. More critically, T-VEC launched before checkpoint inhibitors became standard first-line therapy for melanoma. By the time oncologists understood how to sequence immunotherapies, T-VEC had been relegated to a niche role, and Amgen quietly deprioritized it.
Tudriqev arrives in a different world. Checkpoint inhibitors are now universal first-line therapy, which means the population of patients who progress on them is large, well-defined, and growing. By pairing Tudriqev with Opdivo, the combination directly addresses the post-checkpoint-inhibitor gap that T-VEC was never positioned to fill. Whether Replimune can avoid T-VEC's commercial fate depends on pricing, which has not been announced, and on whether oncologists view Tudriqev as a genuine standard of care rather than a last resort.
Strongest Case Against
Three dissenters on the FDA panel had a legitimate concern: the IGNYTE trial had no control group. Every patient received Tudriqev plus Opdivo. Without a randomized comparison, it is impossible to know with certainty how much of the 24.2% response rate is attributable to the virus and how much to the checkpoint inhibitor alone. Rechallenge with anti-PD-1 agents in melanoma produces response rates of 10 to 15 percent in some studies. If the true additive benefit of the virus is only 10 to 14 percentage points, the clinical significance is real but modest. An ongoing confirmatory trial will answer this question. Until it does, Tudriqev's approval rests on a foundation of reasonable but unproven inference.
There is also the pricing unknown. If Replimune prices Tudriqev aggressively, say above $200,000 per treatment course, the accessibility advantage narrows. An injectable virus that costs $250,000 at a community oncology practice is more accessible than a $515,000 cell therapy at a surgical center, but it is not the democratizing force the throughput math implies. Pricing will determine whether Tudriqev's structural advantage translates into population-level impact.
What You Can Do
If you are a melanoma patient who has progressed on immunotherapy: Ask your oncologist about Tudriqev. Unlike Amtagvi, it does not require referral to a specialized surgical center. Your current oncologist may be able to administer it. The key eligibility criterion is having injectable tumor lesions.
If you are an oncologist: Familiarize yourself with intratumoral injection technique for oncolytic viruses. The procedure is straightforward: ultrasound- or CT-guided injection into accessible lesions. The barrier to offering Tudriqev is not infrastructure; it is training and awareness.
If you are a payer or formulary decision-maker: When Replimune announces pricing, run the per-response cost comparison against Amtagvi at $515,000. At a 24.2% ORR, the break-even price point where Tudriqev matches Amtagvi's cost-per-response is approximately $162,000 per course ($515,000 times 24.2 divided by 31.4). Anything below that number makes Tudriqev more cost-effective per responder, in addition to being more accessible.
If you are a biotech investor: Watch two numbers. First, Replimune's pricing announcement, which will determine peak revenue potential. Second, the confirmatory trial's interim analysis. Accelerated approval without confirmatory data is a conditional license. If the randomized trial disappoints, the FDA can and has withdrawn approvals.
Limitations
Throughput estimates for Amtagvi treatment centers are derived from manufacturing capacity constraints and scheduling assumptions, not from published Iovance data on per-center patient volume. Actual throughput may be higher or lower depending on center-specific workflows. Tudriqev's reachable patient estimate of 15,000 assumes broad oncologist adoption, which is not guaranteed for a newly approved therapy. Our 50:1 center ratio is approximate: it compares certified Amtagvi centers (a precisely defined category) to oncology practices capable of intratumoral injection (a broader and less precisely defined category). Tudriqev's price has not been announced, and the economic comparison depends entirely on where Replimune sets it. IGNYTE's lack of a control arm means the true additive benefit of the virus over Opdivo alone has not been quantified in a randomized setting.
The Bottom Line
On Thursday, the FDA approved a herpes virus to fight cancer, and the debate will focus on whether the agency was right to say yes after saying no twice. That debate matters, but it misses the more consequential question. Approximately 14,000 to 20,000 Americans per year exhaust their immunotherapy options for advanced melanoma. Until last week, their only approved alternative required surgery, weeks of manufacturing, and treatment at one of roughly 30 centers in the country. Now there is an injectable virus that works somewhat less often but can be administered at 50 times more locations, by any oncologist with a needle and imaging guidance, on the day the patient walks in. In oncology, reach is survival. A drug that cannot reach a patient cannot save them, regardless of its response rate. On Thursday, a herpes virus changed who gets reached.